Hosted on MSN13d
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...
MyChesCo on MSN6mon
FDA Approves New Pneumococcal Vaccine for Adults
The vaccine showed promising results in clinical trials. Although the prevention of pneumonia caused by specific pneumococcal ...
Too Old to Operate17d
Sex Differences in Pneumococcal Vaccine Effectiveness for PDRH
The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...
PharmiWeb4d
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate ...
Couriermail20d
‘Three-fold challenge’: Immunisation Foundation of Australia warns deadly Pneumococcal disease hits 20-year high
The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...